[CLSTR]
< Back to situations

[ORGANIZATION]

Committee for Medicinal Products for Human Use

Featured in 7 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [EU] [IT]

EMA CHMP and EU Commission medicinal product approvals

3 clusters · 24 sources · last updated

Latest: European Commission approves Ocrevus for pediatric multiple sclerosis

In September 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of 12 new medicines and therapeutic extensions for 11 existing ones. Among the

[ACTIVE] [HEALTH] [US] [IT] [GR]

FDA approves Rasonque; EMA recommends for pancreatic cancer

44 clusters · 321 sources · last updated

Latest: Pancreatic cancer: New research and treatment developments in Greece

On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R

[QUIET] [HEALTH] [DE]

Achondroplasia clinical trial and regulatory developments

3 clusters · 8 sources · last updated

Latest: Ascendis Pharma receives positive EU opinion for achondroplasia drug

Clinical developments for achondroplasia treatments have shown positive results across different therapeutic approaches. Abbisko Therapeutics reported preliminary Phase II data for lavengratinib (ABSK061), an oral FGFR

[QUIET] [HEALTH] [EU]

EMA cancer therapy approval recommendations

2 clusters · 4 sources · last updated

Latest: EMA recommends approval for three new lung and ovarian cancer therapies

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive recommendations for several new cancer therapies. Initially, the CHMP recommended the approval of Lifyorli (relac

Also covered in